Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden

Cancer

Volumn 97, Issue 6, 2003, Pages 1387-1392

  Olsson, Håkan L ^a,b   Ingvar, Christian ^a   Bladström, Anna ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b S Swedish Regional Tumour Registry   (Sweden)

Author keywords

Breast carcinoma; Estradiol; Hazard ratio; Hormone replacement therapy (HRT); Progestins

Indexed keywords

ESTRADIOL; ESTRIOL; GESTAGEN;

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER RISK; DRUG USE; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; INTERVIEW; LONG TERM CARE; MAJOR CLINICAL STUDY; MENOPAUSE; MORBIDITY; ONCOGENE; PRIORITY JOURNAL; SWEDEN;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROGESTINS; RISK FACTORS; SWEDEN; TIME FACTORS;

EID: 0037443689     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11205     Document Type: Article

References (21)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 49 epidemiological studies involving 51, 977 women with breast cancer and 107, 283 women without breast cancer. Lancet. 1997;350:1047-1059.
2. Olsson H, Bladström A, Ingvar C, Möller T. A population based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer. 2001;85:674-677.
3. Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer. 1986;54:825-832.
4. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol. 1990;97:1080-1086.
5. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat. 1996;38:325-334.
6. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin OncoL 1998;16:3115-3120.
7. O'Connor IF, Shembekar MV, Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol. 1998;51:935-938.
8. Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989;130:221-228.
9. Yuen J, Persson I, Bergkvist L, Hoover R, Schairer C, Adami HO. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect. Cancer Causes Control. 1993;4: 369-374.
10. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127:973-980.
11. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 1999;91:264-270.
12. Jernström H, Frenander J, Fernö M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never use among 984 breast cancer patients. Br J Cancer. 1999;80: 1453-1458.
13. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int J Cancer. 1999;81:339-344.
14. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin [see comments]. J Natl Cancer Inst. 2000;92:328-332.
15. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [see comments]. JAMA. 2000;283:485-491.
16. Investigators WHIRCT. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288:321-333.
17. Cox DR. Regression models and life tables. J R Stat Soc [B]. 1972;34:187-200.
18. Persson I, Bergkvist L, Lindgren C, Yuen J. Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. J Clin Epidemiol. 1997;50:611-618.
19. Persson I, Bergkvist L, Adami H. Reliability of women's histories of climacteric oestrogen treatment assessed by prescription forms. Int J Epidemiol. 1987;16:222-228.
20. Goodman MT, Nomura AM, Wilkens LR, Kolonel LN. Agreement between interview information and physician records on history of menopausal estrogen use [see comments]. Aro J Epidemiol. 1990;131:815-825.
21. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336: 1769-1775.